Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.77 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5023052 | 0.94 | HRH3 (0.71) | HRH3HRH4CYP2D6AKR1C3KMT2A | |
| SCHEMBL5023060 | 0.94 | HRH3 (0.71) | HRH3HRH4CYP2D6AKR1C3KMT2A | |
| SCHEMBL1375924 | 0.87 | HRH3 (1.00) | HRH3CYP2D6 | |
| SCHEMBL1397963 | 0.86 | HRH3 (0.75) | HRH3HRH4CYP2D6KMT2AMEN1 | |
| SCHEMBL1397970 | 0.84 | HRH3 (0.74) | HRH3HRH4CYP2D6AKR1C3KMT2A | |
| SCHEMBL5025822 | 0.83 | HRH3 (0.89) | HRH3CYP2D6 | |
| SCHEMBL5016987 | 0.83 | HRH3 (0.89) | HRH3CYP2D6 | |
| SCHEMBL5016990 | 0.83 | HRH3 (0.89) | HRH3CYP2D6 | |
| Hydrochloric Acid SCHEMBL3246790 | 0.80 | HRH3 (0.81) | HRH3HRH4 | |
| SCHEMBL5016937 | 0.80 | HRH3 (0.65) | HRH3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957479-B1 | 1,5-SUBSTITUTED INDOL-2-YL AMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | disclosed |
| US-7745479-B2 | 1,5-substituted indol-2-yl amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-06-29 | — | — | US | disclosed |
| EP-1957479-A2 | 1,5-SUBSTITUTED INDOL-2-YL AMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007062999-A2 | 1,5-SUBSTITUTED INDOL-2-YL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070123515-A1 | 1,5-Substituted indol-2-yl amide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123515-A1 | 1,5-Substituted indol-2-yl amide derivatives | HRH4, HRH3, HRH2 | HRH3 2/4885HRH4 1/4885CYP2D6 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.